Inside the Issue: Current and Future Management of ER-Positive Metastatic Breast Cancer After Disease Progression on a CDK4/6 Inhibitor

Dr Aditya Bardia from Massachusetts General Hospital in Boston, Massachusetts, and Dr Erika Hamilton from Sarah Cannon Research Institute in Nashville, Tennessee, discuss approved and novel treatment approaches for ER-positive metastatic breast cancer that has progressed on prior CDK4/6 inhibitor therapy.